PMID- 8415473
OWN - NLM
STAT- MEDLINE
DCOM- 19931027
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 22
IP  - 24
DP  - 1993 Jul 3-10
TI  - [Anxiety-related and depressive disorders in women during the premenopausal and 
      menopausal period. Study of the efficacy and acceptability of tianeptine versus 
      maprotiline].
PG  - 1133-8
AB  - This study was conducted to evaluate the effectiveness and acceptability of 
      Tianeptine (T) versus Maprotiline (M) in the management of anxiodepressive 
      disorders in menopausal and premenopausal women. Anxio-depressive women with a 
      Montgomery Asberg Depression score (MADRS) > 20 and a Hamilton Anxiety score 
      (HARS) > 15 were included in the study. T or M were the only psychotropes taken 
      by the patients during the study. Eighty-three women were enrolled and given, by 
      double blind assignment T 37.5 mg/day or M 75 mg/day (T n = 42; M n = 41). The 
      effectiveness of therapy was assessed on D5, D15, D30 and D60 by the MADRS, HARS, 
      CGI and CHESS scores; acceptability was assessed by the CHESS scale. To exclude 
      placebo responders, the patients were treated with a placebo for 7 days prior to 
      enrollment. A significant improvement in the MADRS score, compared with the 
      previous score, remained until D60 for the T group and M group (p < 0.01). The 
      improvement in the MADRS score was higher (p = 0.025) in the T group than in the 
      M group. At D60, there was a statistically significant difference between T and M 
      in favour of T (p = 0.04). Similar results were obtain with HARS and CGI (item 
      1). The incidence of side effect was significantly lower in the group treated 
      with T than in the group treated with M. At any time point, there were more 
      patients in the M group (p < 0.001) who complained of side effects than in the T 
      group. The patients were divided into subgroups according to whether or not they 
      were also receiving Hormone Replacement Therapy (HRT). The group taking HRT and T 
      had a more significant reduction in HARS (p = 0.038) and CHESS (p = 0.015) than 
      the group taking T only. T administrated as a single psychotropic agent showed an 
      improvement in the symptoms of anxio-depression which were significantly more 
      important than in the control group with better control of associated complaints.
FAU - Chaby, L
AU  - Chaby L
AD  - Centre de la Menopause, Hopital Rothschild, Paris.
FAU - Grinsztein, A
AU  - Grinsztein A
FAU - Weitzman, J J
AU  - Weitzman JJ
FAU - de Bodinat, C
AU  - de Bodinat C
FAU - Dagens, V
AU  - Dagens V
LA  - fre
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Etats anxio-depressifs de la femme en periode premenopausique et menopausique. 
      Etude de l'efficacite et de l'acceptabilite de la tianeptine versus maprotiline.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Antidepressive Agents, Tricyclic)
RN  - 0 (Thiazepines)
RN  - 0T493YFU8O (tianeptine)
RN  - 2U1W68TROF (Maprotiline)
SB  - IM
MH  - Antidepressive Agents, Tricyclic/adverse effects/*therapeutic use
MH  - Anxiety Disorders/*drug therapy
MH  - Depressive Disorder/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Maprotiline/adverse effects/*therapeutic use
MH  - *Menopause
MH  - Middle Aged
MH  - Patient Compliance
MH  - Thiazepines/adverse effects/*therapeutic use
EDAT- 1993/07/03 00:00
MHDA- 1993/07/03 00:01
CRDT- 1993/07/03 00:00
PHST- 1993/07/03 00:00 [pubmed]
PHST- 1993/07/03 00:01 [medline]
PHST- 1993/07/03 00:00 [entrez]
PST - ppublish
SO  - Presse Med. 1993 Jul 3-10;22(24):1133-8.